Rocket Lab Earnings Greatly Exceed Expectations, Ignoring Risks as Stock Price Surges?

The core pillar of Rocket Lab's current valuation expansion is the Neutron medium-lift launch vehicle. According to management, the maiden flight window remains set for the fourth quarter of 2026, and five commercial launch orders have already been signed, including a "largest-ever contract" valued at over $190 million.

However, execution risks for aerospace projects have historically been extremely high. Neutron was originally scheduled for a maiden flight in 2024 but has since been postponed several times. Every phase, from engine testing to full vehicle integration and static fire testing at the launch site, carries the potential for further delays.

Calculations from several investment banks indicate that each quarter of delay for Neutron will directly drag down revenue expectations for 2027-2028 by approximately 10%-15%. Rocket Lab has yet to achieve overall profitability, and its valuation already incorporates the optimistic assumption that "Neutron will launch on schedule and scale up rapidly." Should management signal any delays in future earnings calls, the stock's accumulated gains will face a systemic re-rating.

Following the earnings release, CEO Peter Beck reiterated that the Q4 2026 maiden flight window remains unchanged, calling it an "aggressive but achievable schedule," though execution risks for aerospace projects remain exceptionally high.

The first-quarter net loss narrowed to $45 million, and operating cash flow also improved, though the company remains unprofitable. On a GAAP basis, operating expenses rose 40.2% year-over-year and R&D expenses grew by 46.1%, with nearly all of these expenditures directed toward upfront investment in Neutron. Under non-GAAP metrics, adjusted EBITDA remains negative. In other words, the company has merely entered a more efficient state of cash burn.

Against a backdrop of tight financing and sustained high interest rates, intensive capital expenditures will continue to weigh on the income statement in the near term. The market is currently pricing in 'profitability on the horizon,' but the actual timeline for earnings remains dependent on order conversion rates and gross margin realization once Neutron enters service. Market estimates suggest this process will take at least four to six quarters.

Rocket Lab's market capitalization has surged to approximately $50 billion, while market estimates place SpaceX's valuation between $1.75 trillion and $2 trillion. Rocket Lab is unable to compete head-to-head with SpaceX in terms of launch frequency, technological maturity, or the Starlink ecosystem.

More critically, SpaceX's Starlink program is occupying significant low-Earth orbit satellite manufacturing and launch resources, potentially squeezing Rocket Lab's commercial order pipeline. The 'differentiated competitive moat' currently priced in by the market requires sustained policy support and a unique customer structure to maintain, and this is by no means guaranteed.

Institutions have aggressively raised price targets following the earnings report: Craig-Hallum hiked its target to $98, Cowen to $120, and Roth MKM to $100.

TipRanks data shows a 12-month average price target of approximately $86.16, meaning the current $105 share price has already surpassed the upper end of institutional estimates.

In other words, Rocket Lab’s pricing already factors in a series of "perfect assumptions," such as the timely maiden flight of Neutron, smooth order conversion, and a rapid narrowing of losses. Any failure to meet expectations would trigger a sharp correction from its high valuation.

This content was translated using AI and reviewed for clarity. It is for informational purposes only.